Prolonged corticosteroid treatment in acute respiratory distress syndrome: impact on mortality and ventilator-free days
© The Author(s). 2018
Received: 9 February 2018
Accepted: 25 February 2018
Published: 24 May 2018
The Letter to this article has been published in Critical Care 2017 21:327
We read with interest the letter by Blot and colleagues recently published in Critical Care  which concluded that the recommendations of the Corticosteroid Guideline Task Force of SCCM and ESICM  for the use of adjunctive corticosteroids in early moderate to severe acute respiratory distress syndrome (ARDS) were based on insufficient evidence. In support of their view, the authors refer to the meta-analysis of Ruan et al. (reference  in Blot and colleagues’ letter) also published in Critical Care in 2014. We respectfully disagree with their comments and offer the following observations. First, the meta-analysis by Ruan et al. did not take into account how current understanding of disease pathophysiology impacts the administration of corticosteroid treatment in ARDS. The meta-analysis by Ruan et al. incorporated four randomized trials from the 1980s that investigated short-term (24–48 h) massive daily corticosteroid doses (up to 120 mg/kg methylprednisolone equivalent), an intervention that is obsolete and discredited by the present pathophysiological understanding of ARDS . Thus, the inclusion of these trials in the meta-analysis is mostly responsible for the inconsistency reported in their letter. Moreover, the conclusion by Ruan et al. that the benefits of corticosteroid treatment decreased over time are not supported by the actual findings of the cited trials (Figure 3 in , Figure 4 in  and Table 5 in ).
No financial support was received. This letter is the result of work supported with the resources and use of facilities at the Memphis VA Medical Center. The contents of this letter do not represent the views of the US Department of Veterans Affairs or the United States Government.
GUM wrote the first draft and BR, SMP and DA reviewed, edited, and approved the final manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Blot M, Salmon-Rousseau A, Chavanet P, Piroth L. Do we know enough to recommend corticosteroids in acute respiratory distress syndrome? Crit Care. 2017;21(1):327.View ArticlePubMedPubMed CentralGoogle Scholar
- Annane D, Pastores SM, Rochwerg B, et al. Guidelines to the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part 1): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017;45:2078–88.View ArticlePubMedGoogle Scholar
- Annane D, Sebille V, Bellissant E. Ger-Inf-05 Study G: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22–30.View ArticlePubMedGoogle Scholar
- Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159–65.View ArticlePubMedGoogle Scholar
- Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–63.View ArticlePubMedGoogle Scholar